Item 2.02 Results of Operations and Financial Condition.

On January 5, 2022, Albireo Pharma, Inc. ("Albireo") issued a press release (the "Press Release") reporting the preliminary unaudited amount of net sales for the year ended December 31, 2021 of Albireo's product Bylvay and the preliminary unaudited amount of Albireo's cash and cash equivalents for the year ended December 31, 2021. These amounts are preliminary, unaudited and may change, were prepared by management and are based on the most current information available to management, and are subject to completion by management of the financial statements as of and for the year ended December 31, 2021, including completion of the review procedures, final adjustments and other developments that may arise between now and the time the financial results for this period are finalized, and completion of the audit of such financial statements.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 3, 2022, Roger A. Jeffs, Ph.D, a member of the board of directors of Albireo, resigned effective as of January 3, 2022 to pursue other opportunities. Dr. Jeffs' departure was not the result of any disagreement regarding any matter relating to Albireo's operations, policies or practices.

Item 7.01 Regulation FD Disclosure.

The Press Release issued on January 5, 2022 also provides an update on Albireo's BOLD Phase 3 study in biliary atresia and Albireo's ASSERT Phase 3 study in Alagille syndrome and announces the departure of Dr. Jeffs from Albireo. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits




Exhibit No.   Description

  99.1          Press Release issued by Albireo Pharma, Inc. on January 5, 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses